OPKO Health, Inc. (0KCS.L)

1.2204 -0.0201 (-1.62%) At close: 06:49PM BST

OPKO Health, Inc.

4400 Biscayne Boulevard
Miami, FL 33137
United States
305 575 4100
https://www.opko.com

Sector(s): 
Industry: 
Full-time employees: 3,930

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Phillip Frost Ph.D.	Chairman & CEO	1.45M	N/A	1936
Dr. Jane H. Hsiao M.B.A., Ph.D.	Vice Chairman & Chief Technical Officer	1.36M	N/A	1947
Dr. Elias Adam Zerhouni M.D.	President & Vice Chairman	1.36M	N/A	1951
Mr. Adam E. Logal	Senior VP, CFO, Chief Accounting Officer & Treasurer	1.09M	N/A	1978
Mr. Steven D. Rubin Esq., J.D.	Executive VP of Administration & Director	1.22M	N/A	1960
Dr. Akhtar Ashfaq FACP, FASN, M.D.	Senior Vice President of Clinical Research & Development and Medical Affairs - Opko Renal	N/A	N/A	N/A
Dr. Gary J. Nabel M.D., Ph.D.	Chief Innovation Officer & Director	N/A	N/A	1955
Dr. Charles W. Bishop	Chief Executive Officer of OPKO Renal	N/A	N/A	1952
Dr. Antonio F. Cruz	President of Transition Therapeutics	N/A	N/A	1953
Mr. Hans Berner	President of OPKO Health Iberoamerica	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Corporate governance

OPKO Health, Inc.’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 7; Board: 10; Shareholder rights: 3; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.